Effect of Xingbi Gel Nasal Drops on Rats with Allergic Rhinitis Based on the Nasal Mucosa-Hippocampus Neuroimmune Mechanism by FAN Xueqi, QIU Caixia, YAN Shuiping, ZHUANG Xiangli, AI Si, GUO Lihua, ZHENG Jian

“…The AR rat behavioral scoring criteria was used to evaluate rhinitis behavior of rats; Morris water maze test was used to evaluate learning and memory function of rats; enzyme-linked immunosorbent assay (ELISA) was used to detect serum levels of immunoglobulin E (IgE) and transforming growth factor-β1 (TGF-β1); hematoxylin-eosin (HE) staining was used to observe pathological changes of nasal mucosa and eosinophil (EOS) count; immunohistochemistry method was used to detect expression levels of non-receptor tyrosine kinases Fyn, substance P (SP), vasoactive intestinal peptide (VIP) and neuropeptide Y (NPY) in the hippocampus; and real-time polymerase chain reaction (RT-PCR) was used to detect mRNA transcription levels of Fyn, SP, VIP and NPY in the hippocampus.Results(1) Behavioral scores of rhinitis: compared with the normal group, behavioral scores of rhinitis were significantly higher in the model group, the traditional Chinese medicine group and the western medicine group before treatment (<italic>P</italic>&lt;0.05). …”
Get full text

Overview of Prognosis of FLT3 Mutations and Interactions with Other Genetic Alterations in Acute Myeloid Leukemia by Ayşe Gül Bayrak Tokaç, Aynur Dağlar Aday

“…In this letter, we emphasized the prognostic importance of a crucial biomarker in acute myeloid leukemia (AML) – the Fms - like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase that plays a significant role in several cellular signalling processes. …”
Get full text

Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation by Stephen E. Langabeer, Stuart Macleod, Úna Bhreathnach, Kamal Fadalla

“…Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). …”
Get full text

Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients by Ghaleb Elyamany, Mohammad Awad, Kamal Fadalla, Mohamed Albalawi, Mohammad Al Shahrani, Abdulaziz Al Abdulaaly

“…The Fms-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase that plays a key role in cell survival, proliferation, and differentiation of hematopoietic stem cells. …”
Get full text

Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells by Ahmad Hamad, Zeyad Sahli, Maya El Sabban, Maha Mouteirik, Rihab Nasr

“…Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. …”
Get full text

Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case Discussion by Candace Wu, Kamal Shemisa

“…Sorafenib, an oral tyrosine kinase inhibitor (TKI), targets multiple tyrosine kinase receptors (TKRs) involved in angiogenesis and tumor growth. …”
Get full text

Gastrointestinal stromal tumors by A. P. Seryakov

“…Diagnostics, treatment and outcome at patients with GIST underwent significant changes for last 10 years due to discovering of molecular mechanisms, resulting in development of tumor: activated mutations of KITand PDGFR α-tyrosine kinase. These findings promoted development of tyrosine kinase inhibitor – imatinib which demonstrated essential advantage in terms of survival rate of patients. …”
Get full text

Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report by Stefanie Klampfleitner, Andreas Fertl, Ositha Prinz, Martin Doerfler-Schalm, Dieter Munker, Markus O. Henke

“…Introduction: Nintedanib is a tyrosine kinase inhibitor and has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) since 2020. …”
Get full text

Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer by Mikito Inokuchi, Yoshitaka Fujimori, Sho Otsuki, Yuya Sato, Masatoshi Nakagawa, Kazuyuki Kojima

“…Preclinical studies in animal models suggest that multitargeted tyrosine kinase inhibitors (TKIs), including FGFR inhibitor, suppress tumor cell proliferation and delay tumor progression. …”
Get full text

Co-Expression of Plexin-B1 and Met in Human Breast and Ovary Tumours Enhances the Risk of Progression by Guido Valente, Giuseppina Nicotra, Marisa Arrondini, Roberta Castino, Lorena Capparuccia, Maria Prat, Simonetta Kerim, Luca Tamagnone, Ciro Isidoro

“…The binding of Sema4D to Plex-B1 can trigger the activation of Met tyrosine kinase, thereby promoting cell dissociation and invasive growth. …”
Get full text

Flt3 Regulation in the Mononuclear Phagocyte System Promotes Ocular Neovascularization by Yushuo Gao, Yisheng Zhong, Yanji Zhu, Anna M. Demetriades, Yujuan Cai, Jikui Shen, Qing Lu, Xi Shen, Bing Xie

“…Fms-like tyrosine kinase 3 (Flt3), a tyrosine kinase receptor expressed in CD34+ hematopoietic stem/progenitor cells, is important for both normal myeloid and lymphoid differentiation. …”
Get full text

Hepatocyte Growth Factor in Synaptic Plasticity and Alzheimer's Disease by Shiv K. Sharma

“…HGF signaling, which is initiated by its binding to a receptor tyrosine kinase, plays critical roles during development. …”
Get full text

Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability by Huiling Su, Jie Shen, Chenzi Gao, Yue Zhao, Wanyu Deng, Bo Qin, Xin Zhang, Juan Lai, Qian Wang, Jie Dou, Min Guo

“…Notably, mutations in the EGFR tyrosine kinase domain, which typically confer resistance to TKIs, did not alter the regulatory effect of EPN3. …”
Get full text

Detection of fusion events by RNA sequencing in FFPE versus freshly frozen colorectal cancer tissue samples by Maxim Sorokin, Maxim Sorokin, Maxim Sorokin, Maxim Sorokin, Vladimir Lyadov, Vladimir Lyadov, Vladimir Lyadov, Maria Suntsova, Marat Garipov, Anna Semenova, Natalia Popova, Egor Guguchkin, Rustam Heydarov, Marianna Zolotovskaia, Xiaowen Zhao, Qing Yan, Ye Wang, Evgeny Karpulevich, Anton Buzdin, Anton Buzdin, Anton Buzdin, Anton Buzdin

“…Specific targeted therapies are available for several types of cancer fusions including receptor tyrosine kinase gene moieties. RNA sequencing (RNAseq) can directly be used for detection of gene rearrangements in a single test, along with multiple additional biomarkers. …”
Get full text

Squamous Cell Carcinoma of the Lung with Metastasis to the GI Tract Associated with EGFR Exon 19 Deletion by Glen J. Weiss, Agnes K. Liman, Jeffrey Allen, Philip Y. Cheung, Rajesh N. Kukunoor

“…One of these patients received EGFR tyrosine kinase directed therapy for a brief period with some symptom relief. …”
Get full text

Discovery of a Novel DYRK1A Mutation (c.524del) in Intellectual Development Disorder Autosomal Dominant 7 (MRD7): A Comprehensive Case Analysis by Fiona Whitaker, Alvaro Serrano

“…Dual-specificity tyrosine kinase 1A (DYRK1A) is a member of the CMGC family that is linked to a multitude of neuronal development pathways. …”
Get full text

A rare vascular manifestation in chronic myeloid leukemia: a case report and literature review of Bier's spot development during nilotinib treatment by Ahmed Alsaati, Turki Hakami, Sultan Bajawi, Gamil Mohammed, Nouf Bajawi, Nadya Al-Faraidy

“…This case emphasizes the need to recognize potential vascular side effects of tyrosine kinase inhibitors and highlights Bier's spots as a benign but remarkable manifestation in patients undergoing nilotinib therapy. …”
Get full text

A case of pityriasis rubra pilaris secondary to ponatinib by Ariana Nateghi, Florence Lagacé-Thomassin, Julie Desrochers

“…Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. …”
Get full text

Treatment approaches in advanced penile cancer: targeted therapies and immunotherapy by David J. Benjamin, Robert C. Hsu

“…Several ongoing trials involving immune checkpoint inhibitors, tyrosine kinase inhibitors, and antibody drug conjugates are attempting to identify additional therapies.…”
Get full text

New Strategies and In Vivo Monitoring Methods for Stem Cell-Based Anticancer Therapies by Ping Wang, Aitor Aguirre

“…Despite significant advances in recent years, such as the introduction of targeted therapies such as receptor tyrosine kinase inhibitors and immunotherapy, current approaches are insufficient to stop the advance of the disease and many cancer types remain largely intractable. …”
Get full text